Vedolizumab IV in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)
Completed · Phase 2 · NCT03138655
Conditions: Ulcerative Colitis, Crohn's Disease
At a glance
- Research payments reported, 2025
- $5,259
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 89
About the trial
- Sponsor
- Takeda (with Takeda Development Center Americas, Inc.)
- Tested
- Vedolizumab (drug)
- Dates
- Started 2017-11-08; completion 2020-05-26
- Results posted
- Yes
The purpose of this study is to evaluate vedolizumab pharmacokinetics (PK), safety and tolerability in pediatric participants with moderately to severely active UC or CD.
From ClinicalTrials.gov, last updated 2020-12-21. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Takeda Pharmaceuticals U.S.A., Inc. reported $5,259 in research payments for this study in 2025 (4 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Trustees of Columbia University in The City of New York $5,259
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.